In Depth Partners LLC Sells 9,596 Shares of Zoetis Inc. $ZTS

Key Points

• In Depth Partners LLC sold 9,596 shares of Zoetis Inc., reducing its stake by 52.5%, leaving it with 8,678 shares worth approximately $1.43 million.
• Several hedge funds have increased their holdings in Zoetis, with Portside Wealth Group LLC raising its stake by 24.7% and Tandem Investment Advisors Inc. boosting theirs by over 100% in the first quarter.
• Zoetis recently reported a quarterly earnings per share of $1.76, exceeding analyst expectations, and set guidance of $6.30 to $6.40 EPS for Fiscal Year 2025.

In Depth Partners LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 52.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,678 shares of the company's stock after selling 9,596 shares during the period. Zoetis accounts for about 1.6% of In Depth Partners LLC's portfolio, making the stock its 13th biggest holding. In Depth Partners LLC's holdings in Zoetis were worth $1,429,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Portside Wealth Group LLC boosted its stake in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after acquiring an additional 6,672 shares during the period. Tandem Investment Advisors Inc. boosted its stake in shares of Zoetis by 100.3% in the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after acquiring an additional 198,089 shares during the period. Flagship Harbor Advisors LLC boosted its stake in shares of Zoetis by 31.2% in the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after acquiring an additional 1,760 shares during the period. Horizon Financial Services LLC bought a new position in shares of Zoetis in the first quarter worth about $380,000. Finally, Sage Rhino Capital LLC boosted its stake in shares of Zoetis by 117.6% in the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after acquiring an additional 3,791 shares during the period. Institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.18% of the stock is currently owned by company insiders.

Zoetis Trading Up 0.5%

Shares of ZTS stock opened at $156.3180 on Friday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock's 50 day simple moving average is $153.84 and its two-hundred day simple moving average is $158.52. The company has a market cap of $69.28 billion, a PE ratio of 26.91, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The company's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZTS. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, Zoetis has a consensus rating of "Moderate Buy" and an average target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.